| 词条 | Maroteaux–Lamy syndrome |
| 释义 |
| name = Maroteaux–Lamy syndrome | synonyms = | image = Autosomal recessive - en.svg | caption = This condition is inherited in an autosomal recessive manner. | pronounce = | field = | symptoms = | complications = | onset = | duration = | types = | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = | frequency = | deaths = }}Maroteaux–Lamy syndrome (also known as mucopolysaccharidosis type VI,[1] MPS VI, or polydystrophic dwarfism) is a form of mucopolysaccharidosis caused by a deficiency in arylsulfatase B (ARSB).[2] It is named after Pierre Maroteaux (1926–) and his mentor Maurice Emil Joseph Lamy (1895–1975), both French physicians.[3][4] SymptomsChildren with Maroteaux–Lamy syndrome usually have normal intellectual development but share many of the physical symptoms found in Hurler syndrome. Caused by the deficient enzyme N-acetylgalactosamine 4-sulfatase, Maroteaux–Lamy syndrome has a variable spectrum of severe symptoms. Neurological complications include clouded corneas, deafness, thickening of the dura (the membrane that surrounds and protects the brain and spinal cord), and pain caused by compressed or traumatized nerves and nerve roots. Signs are revealed early in the affected child's life, with one of the first symptoms often being a significantly prolonged age of learning how to walk.[5] By age 10 children have developed a shortened trunk, crouched stance, and restricted joint movement. In more severe cases, children also develop a protruding abdomen and forward-curving spine. Skeletal changes (particularly in the pelvic region) are progressive and limit movement. Many children also have umbilical hernia or inguinal hernias. Nearly all children have some form of heart disease, usually involving valve dysfunction. TreatmentAn enzyme replacement therapy, galsulfase (Naglazyme), was tested on patients with Maroteaux–Lamy syndrome and was successful in that it improved growth and joint movement. An experiment was then carried out to see whether an injection of the missing enzyme into the hips would help the range of motion and pain. At a cost of $365,000 a year, Naglazyme is one of the world's most expensive drugs.[6] See also
References1. ^{{cite book |author=Rapini, Ronald P. |author2=Bolognia, Jean L. |author3=Jorizzo, Joseph L. |title=Dermatology: 2-Volume Set |publisher=Mosby |location=St. Louis |year=2007 |pages= |isbn=978-1-4160-2999-1 |oclc= |doi= |accessdate=}} 2. ^{{cite journal |vauthors=Garrido E, Cormand B, Hopwood JJ, Chabás A, Grinberg D, Vilageliu L |title=Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene |journal=Mol. Genet. Metab. |volume=94 |issue=3 |pages=305–12 |date=July 2008 |pmid=18406185 |doi=10.1016/j.ymgme.2008.02.012 |url=http://linkinghub.elsevier.com/retrieve/pii/S1096-7192(08)00057-7}} 3. ^{{WhoNamedIt|synd|1619}} 4. ^{{cite journal |vauthors=MAROTEAUX P, LEVEQUE B, MARIE J, LAMY M |title=[A NEW DYSOSTOSIS WITH URINARY ELIMINATION OF CHONDROITIN SULFATE B.] |language=French |journal=Presse Med |volume=71 |issue= |pages=1849–52 |date=September 1963 |pmid=14091597 |doi= |url=}} 5. ^{{cite news| url=http://www.chicagotribune.com/news/local/breaking/chibrknews-web-wonder-kid-its-keenans-world-for-now-20110414,0,2983797,print.story | work=Chicago Tribune | title=Topic Galleries}} 6. ^{{cite news| url=http://www.alternet.org/personal-health/9-most-expensive-medicines-world-courtesy-big-pharma |author= Larry Schwartz | work= AlterNet | title=The 9 Most Expensive Medicines in the World–Courtesy of Big Pharma}} External links{{Medical resources| DiseasesDB = ddb29179 | ICD10 = {{ICD10|E|76|2|e|70}} | ICD9 = {{ICD9|277.5}} | ICDO = | OMIM = 253200 | MedlinePlus = | eMedicineSubj = ped | eMedicineTopic = 1373 | MeshID = D009087 }}
3 : Proteoglycan metabolism disorders|Skin conditions resulting from errors in metabolism|Syndromes |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。